R&D | March 28, 2026
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
As Tracky launches integrated health solution
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
